Terbinafine: a pharmacological and clinical review

Bibliography

• Shear NH, Villars VV, Marsolais C. Terbinafine: an oral and topical antifungal agent. Clin Dermatol 1991;9:487-95
   PubMed Web of Science ®Google Scholar
• Elewski BE, Hay RJ. Update on the management of onychomycosis: highlights of the third annual international summit on cutaneous antifungal therapy. Clin Infect Dis 1996;23:305-13
   PubMedGoogle Scholar
• Gupta AK, Cooper EA. Update in antifungal therapy of dermatophytosis. Mycopathologia 2008;166:353-67
   PubMed Web of Science ®Google Scholar
• Ryder NS. Activity of terbinafine against serious fungal pathogens. Mycoses 1999;42(Suppl 2):115-19
   Google Scholar
• Gupta AK, Konnikov N, Lynde CW. Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly. J Am Acad Dermatol 2001;44:479-84
   PubMed Web of Science ®Google Scholar
• Elewski BE, Cáceres HW, DeLeon L, Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with Tinea capitis: results of two randomized, investigator-blinded, multicenter, international, controlled trials. J Am Acad Dermatol 2008;59:41-54
   PubMed Web of Science ®Google Scholar
• Revankar SG, Nailor MD, Sobel JD. Use of terbinafine in rare and refractory mycoses. Future Microbiol 2008;3:9-17
   PubMedGoogle Scholar
• Gupta AK, Ryder JE, Lynch LE, Tavakkol A. The use of terbinafine in the treatment of onychomycosis in adults and special populations: a review of the evidence. J Drugs Dermatol 2005;4:302-8
   PubMedGoogle Scholar
• Favre B, Ryder NS. Characterization of squalene epoxidase activity from the dermatophyte Trichophyton rubrum and its inhibition by terbinafine and other antimycotic agents. Antimicrob Agents Chemother 1996;40:443-7
   PubMed Web of Science ®Google Scholar
• Ryder NS. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol 1992;126:2-7
   PubMed Web of Science ®Google Scholar
• Jensen JC. Clinical pharmacokinetics of terbinafine (Lamisil). Clin Exp Dermatol 1989;14:110-13
   PubMed Web of Science ®Google Scholar
• Schäfer-Korting M, Schoellmann C, Korting HC. Fungicidal activity plus reservoir effect allow short treatment courses with terbinafine in tinea pedis. Skin Pharmacol Physiol 2008;21:203-10
   PubMedGoogle Scholar
• Zehender H, Cabiac MD, Denouël J, Elimination kinetics of terbinafine from human plasma and tissues following multiple-dose administration, and comparison with 3 main metabolites. Drug Invest 1994;8:203-10
   Web of Science ®Google Scholar
• Balfour JA, Faulds D. Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs 1992;43:259-84
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Mueller EA, Zehender H, Multiple-dose pharmacokinetics and distribution in tissue of terbinafine and metabolites. Antimicrob Agents Chemother 1995;39:2738-41
   PubMed Web of Science ®Google Scholar
• Faergemann J, Zehender H, Denouël J, Millerioux L. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks. Acta Derm Venereol 1993;73:305-9
   PubMed Web of Science ®Google Scholar
• Nedelman JR, Gibiansky E, Robbins BA, Pharmacokinetics and pharmacodynamics of multiple-dose terbinafine. J Clin Pharmacol 1996;36:452-61
   PubMedGoogle Scholar
• Finlay AY. Pharmacokinetics of terbinafine in the nail. Br J Dermatol 1992;126(Suppl 39):28-32
   PubMedGoogle Scholar
• Torres-Rodriguez JM, Madrenys-Brunet N, Urrea-Arbeláez A, Lopez-Jodra O. Oral terbinafine for the Tinea unguium of the toenails. Efficacy between 12 and 24 weeks of treament. Rev Iberoam Micol 1998;15:160-2
   PubMedGoogle Scholar
• Takahata Y, Hiruma M, Shiraki Y, Treatment of dermatophyte onychomycosis with three pulses of terbinafine (500 mg day for a week). Mycoses 2009;52:72-6
   PubMed Web of Science ®Google Scholar
• Gupta AK, Gover MD, Lynde CW. Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus. J Eur Acad Dermatol Venereol 2006;20:1188-93
   PubMed Web of Science ®Google Scholar
• Nardo Zaias MD, Gerbert Rebell MS. The successful treatment of Trichophyton rubrum nail bed (distal subungual) onychomycosis with intermittent pulse-dosed terbinafine. Arch Dermatol 2004;140:691-95
   PubMedGoogle Scholar
• Hall M, Monka C, Krupp P, O'Sullivan D. Safety of oral terbinafine: results of a post-marketing surveillance study in 25884 patients. Arch Dermatol 1997;133:1213-19
   PubMed Web of Science ®Google Scholar
• Yülek F, Cagil N, Cakmak HB, Bilateral anterior optic neuropathy associated with use of terbinafine. Clin Exp Ophthalmol 2008;36:488-9
   PubMedGoogle Scholar
• Tokuyama Y, Senoh A, Setsu N, Iwatsuki K. Pustular psoriasis induced by terbinafine: differential diagnosis from acute generalized exanthematous pustulosis. Eur J Dermatol 2008;18:725-6
   PubMed Web of Science ®Google Scholar
• Magro CM, Schaefer JT, Waldman J, Terbinafine-induced dermatomyositis: a case report and literature review of drug-induced dermatomyositis. J Cutan Pathol 2008;35:74-81
   PubMedGoogle Scholar
• Paredes AH, Lewis JH. Terbinafine-induced acute autoimmune hepatitis in the setting of hepatitis B virus infection. Ann Pharmacother 2007;41:880-4
   PubMed Web of Science ®Google Scholar
• Perveze Z, Johnson MW, Rubin RA, Terbinafine-induced hepatic failure requiring liver transplantation. Liver Transpl 2007;13:162-4
   PubMed Web of Science ®Google Scholar
• Vickers AE, Sinclair JR, Zollinger M, Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab Dispos 1999;27:1029-38
   PubMed Web of Science ®Google Scholar
• Madani S, Barilla D, Cramer J, Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers. J Clin Pharmacol 2002;42:1211-18
   PubMed Web of Science ®Google Scholar
• Tarral A, Francheteau P, Guerret M. Effects of terbinafine on the pharmacokinetics of digoxin in healthy volunteers. Pharmacotherapy 1997;17:791-5
   PubMedGoogle Scholar
• Guerret M, Francheteau P, Hubert M. Evaluation of effects of terbinafine on single oral dose pharmacokinetics and anticoagulant actions of warfarin in healthy volunteers. Pharmacotherapy 1997;17:767-73
   PubMedGoogle Scholar
• Lo AC, Lui SL, Lo WK, The interaction of terbinafine and cyclosporine A in renal transplant patients. Br J Clin Pharmacol 1997;43:340-1
   PubMedGoogle Scholar
• Carrillo-Muñoz AJ, Gustavo Giusiano G, Cárdenes D, Terbinafine susceptibility patterns for onychomycosis-causative dermatophytes and Scopulariopsis brevicaulis. Int J Antimicrob Agents 2008;31:540-3
   PubMed Web of Science ®Google Scholar
• Ghannoum MA, Arthington-Skaggs B, Chaturvedi V, Interlaboratory study of quality control isolates for a broth microdilution method (modified CLSI M38-A) for testing susceptibilities of dermatophytes to antifungals. J Clin Microbiol 2006;44:4353-6
   PubMed Web of Science ®Google Scholar
• Figueiredo VT, de Assis Santos D, Resende MA, Hamdan JS. Identification and in vitro antifungal susceptibility testing of 200 clinical isolates of Candida spp. responsible for fingernail infections. Mycopathologia 2007;164:27-33
   PubMed Web of Science ®Google Scholar
• Córdoba S, Rodero L, Vivot W, In vitro interactions of antifungal agents against clinical isolates of Fusarium spp. Int J Antimicrob Agents 2008;31:171-4
   PubMed Web of Science ®Google Scholar
• Meinerz AR, Nascente Pda S, Schuch LF, In vitro susceptibility of isolates of Sporothrix schenckii to terbinafine and itraconazole. Rev Soc Bras Med Trop 2007;40:60-2
   PubMedGoogle Scholar
• Queiroz-Telles F, Esterre P, Perez-Blanco M, Chromoblastomycosis: an overview of clinical manifestations, diagnosis and treatment. Med Mycol 2009;47:3-15
   PubMed Web of Science ®Google Scholar
• Vitale RG, Perez-Blanco M, De Hoog GS. In vitro activity of antifungal drugs against Cladophialophora species associated with human chromoblastomycosis. Med Mycol 2009;47:35-40
   PubMed Web of Science ®Google Scholar
• Ford JG, Agee S, Greenhaw ST. Successful medical treatment of a case of Paecilomyces lilacinus keratitis. Cornea 2008;27:1077-9
   PubMed Web of Science ®Google Scholar
• McGinnis MR, Nordoff NG, Ryder NS, Nunn GB. In vitro comparison of terbinafine and itraconazole against Penicillium marneffei. Antimicrob Agents Chemother 2000;44:1407-8
   PubMedGoogle Scholar
• Contini C, Manganaro M, Romani R, Activity of terbinafine against Pneumocystis carinii in vitro and its efficacy in the treatment of experimental pneumonia. J Antimicrob Chemother 1994;34:727-35
   PubMedGoogle Scholar
• Jessup CJ, Ghannoum MA, Ryder NS. An evaluation of the in vitro activity of terbinafine. Med Mycol 2000;38:155-9
   PubMed Web of Science ®Google Scholar
• Ryder NS, Wagner S, Leitner I. In vitro activities of terbinafine against cutaneous isolates of Candida albicans and other pathogenic yeasts. Antimicrob Agents Chemother 1998;42:1057-61
   PubMed Web of Science ®Google Scholar
• Dannaoui E, Meletiadis J, Mouton JW, ; Eurofung Network. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother 2003;51:45-52
   PubMed Web of Science ®Google Scholar
• Ghannoum MA, Long L, Pfister WR. Determination of the efficacy of terbinafine hydrochloride nail solution in the topical treatment of dermatophytosis in a guinea pig model. Mycoses 2009;52:35-43
   PubMed Web of Science ®Google Scholar
• Petranyi G, Meingassner JG, Mieth H. Activity of terbinafine in experimental fungal infections of laboratory animals. Antimicrob Agents Chemother 1987;31:1558-61
   PubMed Web of Science ®Google Scholar
• Walzer PD, Ashbaugh A. Use of terbinafine in mouse and rat models of Pneumocystis carinii pneumonia. Antimicrob Agents Chemother 2002;46:514-16
   PubMedGoogle Scholar
• Contini C, Colombo D, Cultrera R, Employment of terbinafine against Pneumocystis carinii infection in rat models. Br J Dermatol 1996;134(Suppl 46):30-2
   PubMedGoogle Scholar
• Sorenson KN, Sobel RA, Clemons KV, Comparative efficacies of terbinafine and FLZ in treatment of experimental coccidioidal meningitis in a rabbit model. Antimicrob Agents Chemother 2000;44:3087-91
   PubMedGoogle Scholar
• Schmitt HJ, Andrade J, Edwards F, Inactivity of terbinafine in a rat model of pulmonary aspergillosis. Eur J Clin Microbiol Infect Dis 1990;9:832-5
   PubMedGoogle Scholar
• Kirkpatrick WR, Vallor AC, McAtee RK, Combination therapy with terbinafine and amphotericin B in a rabbit model of experimental invasive aspergillosis. Antimicrob Agents Chemother 2005;49:4751-3
   PubMed Web of Science ®Google Scholar
• Urbina JA, Lazardi K, Marchan E, Mevinolin (lovastatin) potentiates the antiproliferative effects of ketoconazole and terbinafine against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Antimicrob Agents Chemother 1993;37:580-91
   PubMed Web of Science ®Google Scholar
• Ford JG, Agee S, Greenhaw ST. Successful medical treatment of a case of Paecilomyces lilacinus keratitis. Cornea 2008;27:1077-9
   PubMed Web of Science ®Google Scholar
• Chang BP, Sun PL, Huang FY, Paecilomyces lilacinus peritonitis complicating peritoneal dialysis cured by oral voriconazole and terbinafine combination therapy. J Med Microbiol 2008;57:1581-4
   PubMedGoogle Scholar
• Kurzai O, Vaeth T, Hamelmann W, Combined surgical and antifungal treatment of a subcutaneous infection due to Paecilomyces lilacinus. Med Mycol 2003;41:253-8
   PubMed Web of Science ®Google Scholar
• Ghannoum MA, Elewski B. Successful treatment of FLZ-resistant oropharyngeal candidiasis by a combination of fluconazole and terbinafine. Clin Diagn Lab Immunol 1999;6:921-3
   PubMedGoogle Scholar
• Rothe A, Seibold M, Hoppe T, Combination therapy of disseminated Fusarium oxysporum infection with terbinafine and amphotericin B. Ann Hematol 2004;83:394-7
   PubMed Web of Science ®Google Scholar
• Neuburger S, Massenkeil G, Seibold M, Successful salvage treatment of disseminated cutaneous fusariosis with liposomal amphotericin B and terbinafine after allogeneic stem cell transplantation. Transpl Infect Dis 2008;10:290-3
   PubMed Web of Science ®Google Scholar
• Schiraldi GF, Cicero SL, Colombo MD, Refractory pulmonary aspergillosis: compassionate trial with terbinafine. Br J Dermatol 1996;134(Suppl 46):25-9
   PubMedGoogle Scholar
• Schiraldi GF, Colombo MD, Harari S, Terbinafine in the treatment of non-immunocompromised compassionate cases of bronchopulmonary aspergillosis. Mycoses 1996;39:5-12
   PubMed Web of Science ®Google Scholar
• Hiromoto A, Nagano T, Nishigori C. Cutaneous infection caused by Curvularia species in an immunocompetent patient. Br J Dermatol 2008;158:1374-5
   PubMedGoogle Scholar
• Sun ST, Wang LY, Xu J, The clinical and pathogenic characteristics of keratitis caused by Alternaria alternata. Zhonghua Yan Ke Za Zhi 2007;43:32-5
   PubMedGoogle Scholar
• Rallis E, Frangoulis E. Successful treatment of subcutaneous phaeohyphomycosis owing to Exophiala jeanselmei with oral terbinafine. Int J Dermatol 2006;45:1369-70
   PubMed Web of Science ®Google Scholar
• Zhang J, Xi L, Lu C, Successful treatment for chromoblastomycosis caused by Fonsecaea monophora: a report of three cases in Guangdong, China. Mycoses 2009;52:176-81
   PubMed Web of Science ®Google Scholar
• Gupta AK, Taborda PR, Sanzova AD. Alternate week and combination itraconazole and terbinafine therapy for chromoblastomycosis caused by Fonsecaea pedrosoi in Brazil. Med Mycol 2002;40:529-34
   PubMed Web of Science ®Google Scholar
• Sriaroon C, Vincent AL, Silapunt S, Successful treatment of subcutaneous Scytalidium hyalinum infection with voriconazole and topical terbinafine in a cardiac transplant patient. Transplantation 2008;85:780-2
   PubMed Web of Science ®Google Scholar
• Li JY, Yong TY, Grove DI, Coates PT. Successful control of Scedosporium prolificans septic arthritis and probable osteomyelitis without radical surgery in a long-term renal transplant recipient. Transpl Infect Dis 2008;10:63-5
   PubMed Web of Science ®Google Scholar
• Bhat SV, Paterson DL, Rinaldi MG, Veldkamp PJ. Scedosporium prolificans brain abscess in a patient with chronic granulomatous disease: successful combination therapy with voriconazole and terbinafine. Scand J Infect Dis 2007;39:87-90
   PubMed Web of Science ®Google Scholar
• Gosbell IB, Toumasatos V, Yong J, Cure of orthopaedic infection with Scedosporium prolificans, using voriconazole plus terbinafine, without the need for radical surgery. Mycoses 2003;46:233-6
   PubMed Web of Science ®Google Scholar
• Howden BP, Slavin MA, Schwarer AP, Mijch AM. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur J Clin Microbiol Infect Dis 2003;22:111-13
   PubMed Web of Science ®Google Scholar
• Kesson AM, Bellemore MC, O'Mara TJ, Scedosporium prolificans osteomyelitis in an immunocompetent child treated with a novel agent, hexadecylphospocholine (miltefosine), in combination with terbinafine and voriconazole: a case report. Clin Infect Dis 2009;48:1257-61
   PubMed Web of Science ®Google Scholar
• Perez A. Terbinafine: broad spectrum of indications in several subcutaneous and systemic parasitic diseases. Mycoses 1999;42:111-14
   Web of Science ®Google Scholar
• Neoh CY, Tan SH, Perera P. Cutaneous phaeohyphomycosis due to Cladophialophora bantiana in an immunocompetent patient. Clin Exp Dermatol 2007;32:539-40
   PubMed Web of Science ®Google Scholar
• Shenep JL, English BK, Kaufman L, Successful medical therapy for deeply invasive facial infection due to Pythium insidiosum in a child. Clin Infect Dis 1998;27:1388-93
   PubMed Web of Science ®Google Scholar
• Meletiadis J, Mouton JW, Rodriguez-Tudela JL, In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans. Antimicrob Agents Chemother 2000;44:470-2
   PubMed Web of Science ®Google Scholar
• Meletiadis J, Mouton JW, Meis JF, Verweij PE. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother 2003;47:106-17
   PubMed Web of Science ®Google Scholar
• Meletiadis J, Mouton JW, Meis JF, Verweij PE. Combination chemotherapy for the treatment of invasive infections by Scedosporium prolificans. Clin Microbiol Infect 2000;6:336-7
   PubMedGoogle Scholar
• Shalit I, Shadkchan Y, Mircus G, Osherov N. In vitro synergy of caspofungin with licensed and novel antifungal drugs against clinical isolates of Fusarium spp. Med Mycol 2008;13:1-6
   Google Scholar
• Li L, Wang Z, Li R, In vitro evaluation of combination antifungal activity against Fusarium species isolated from ocular tissues of keratomycosis patients. Am J Ophthalmol 2008;146:724-8
   PubMed Web of Science ®Google Scholar
• Argenta JS, Santurio JM, Alves SH, In vitro activities of voriconazole, itraconazole, and terbinafine alone or in combination against Pythium insidiosum isolates from Brazil. Antimicrob Agents Chemother 2008;52:767-9
   PubMedGoogle Scholar
• Weig M, Müller FM. Synergism of voriconazole and terbinafine against Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 2001;45:966-8
   PubMed Web of Science ®Google Scholar
• Perea S, Gonzalez G, Fothergill AW, In vitro activities of terbinafine in combination with fluconazole, itraconazole, voriconazole, and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azoles. J Clin Microbiol 2002;40:1831-3
   PubMed Web of Science ®Google Scholar
• Barchiesi F, Falconi Di Francesco L, Scalise G. In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles. Antimicrob Agents Chemother 1997;41:1812-14
   PubMed Web of Science ®Google Scholar
• Cantón E, Pemán J, Gobernado M, Synergistic activities of fluconazole and voriconazole with terbinafine against four Candida species determined by checkerboard, time-kill, and Etest methods. Antimicrob Agents Chemother 2005;49:1593-6
   PubMed Web of Science ®Google Scholar
• Gómez-López A, Cuenca-Estrella M, Mellado E, Rodríguez-Tudela JL. In vitro evaluation of combination of terbinafine with itraconazole or amphotericin B against Zygomycota. Diagn Microbiol Infect Dis 2003;45:199-202
   PubMed Web of Science ®Google Scholar
• Dannaoui E, Afeltra J, Meis JF, Verweij PE; Eurofung Network. In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents. Antimicrob Agents Chemother 2002;46:2708-11
   PubMed Web of Science ®Google Scholar
• Mosquera J, Sharp A, Moore CB, In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp. J Antimicrob Chemother 2002;50:189-94
   PubMed Web of Science ®Google Scholar
• Ryder NS, Leitner I. Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species. Med Mycol 2001;39:91-5
   PubMed Web of Science ®Google Scholar
• Cuenca-Estrella M, Gomez-Lopez A, Buitrago MJ, In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen Scopulariopsis brevicaulis. Antimicrob Agents Chemother 2006;50:2248-50
   PubMed Web of Science ®Google Scholar
• Rangel H, Dagger F, Hernandez A, Naturally azole-resistant Leishmania braziliensis promastigotes are rendered susceptible in the presence of terbinafine: comparative study with azole-susceptible Leishmania mexicana promastigotes. Antimicrob Agents Chemother 1996;40:2785-91
   PubMed Web of Science ®Google Scholar
• Martinez-Rossi NM, Peres NT, Rossi A. Antifungal resistance mechanisms in dermatophytes. Mycopathologia 2008;166:369-83
   PubMed Web of Science ®Google Scholar
• Fachin AL, Ferreira-Nozawa MS, Maccheroni WJr, Martinez-Rossi NM. Role of the ABC transporter TruMDR2 in terbinafine, 4-nitroquinoline N-oxide and ethidium bromide susceptibility in Trichophyton rubrum. J Med Microbiol 2006;55:1093-9
   PubMedGoogle Scholar
• Rocha EM, Gardiner RE, Park S, A Phe389Leu substitution in ergA confers terbinafine resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 2006;50:2533-6
   PubMed Web of Science ®Google Scholar
• Osborne CS, Leitner I, Favre B, Ryder NS. Amino acid substitution in Trichophyton rubrum squalene epoxidase associated with resistance to terbinafine. Antimicrob Agents Chemother 2005;49:2840-4
   PubMed Web of Science ®Google Scholar
• Liu W, May GS, Lionakis MS, Extra copies of the Aspergillus fumigatus squalene epoxidase gene confer resistance to terbinafine: genetic approach to studying gene dose-dependent resistance to antifungals in A. fumigatus. Antimicrob Agents Chemother 2004;48:2490-6
   PubMedGoogle Scholar
• Mukherjee PK, Leidich SD, Isham N, Clinical Trichophyton rubrum strain exhibiting primary resistance to terbinafine. Antimicrob Agents Chemother 2003;47:82-6
   PubMed Web of Science ®Google Scholar
• de Assis Santos D, de Carvalho Araujo RA, Kohler LM, Molecular typing and antifungal susceptibility of Trichophyton rubrum isolates from patients with onychomycosis pre- and post-treatment. Int J Antimicrob Agents 2007;29:563-9
   PubMed Web of Science ®Google Scholar
• Garcia-Effron G, Gomez-Lopez A, Mellado E, In vitro activity of terbinafine against medically important non-dermatophyte species of filamentous fungi. J Antimicrob Chemother 2004;53:1086-9
   PubMed Web of Science ®Google Scholar
• Krishnan-Natesan S, Chandrasekar PH, Manavathu EK, Revankar SG. Successful treatment of primary cutaneous Aspergillus ustus infection with surgical debridement and a combination of voriconazole and terbinafine. Diagn Microbiol Infect Dis 2008;62:443-6
   PubMed Web of Science ®Google Scholar
• Stiller MJ, Teperman L, Rosenthal SA, Primary cutaneous infection by Aspergillus ustus in a 62-year-old liver transplant recipient. J Am Acad Dermatol 1994;31:344-7
   PubMed Web of Science ®Google Scholar
• Bruynzeel I, Starink TM. Granulomatous skin infection caused by Scopulariopsis brevicularis. J Am Acad Dermatol 1998;39:365-7
   PubMed Web of Science ®Google Scholar
• Destino L, Sutton DA, Helon AL, Severe osteomyelitis caused by Myceliophthora thermophila after a pitchfork injury. Ann Clin Microbiol Antimicrob 2006;5:21
   PubMedGoogle Scholar